For example, since 2015, several DUBs-targeted agents, including VLX1570 (targeting USP14), P22077 (targeting USP7/USP10/USP47), P5091 (targeting USP7/USP47), and spautin-1 (targeting USP10/USP13), have been investigated in the clinic to treat certain types of cancers. This evidence concerns the gene USP14 and cancer.